多潘立酮(Domperidone) - 药物靶点：D2 receptor_在研适应症：胃肠道疾病，恶心，呕吐_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Deudomperidone、deuterated domperidone (CinRx Pharma)、Domperidone (JP17/USAN/INN)

+ [8]

靶点

D2 receptor

作用机制

D2 receptor拮抗剂(多巴胺D2受体拮抗剂)

治疗领域

感染消化系统疾病呼吸系统疾病+ [3]

在研适应症

胃肠道疾病恶心呕吐+ [8]

非在研适应症

诺如病毒感染

原研机构-

在研机构

Kyowa Hakko Kirin Pharma, Inc.

Kyowa Kirin Co., Ltd.

西安杨森制药有限公司

+ [1]

非在研机构

Janssen-Cilag International NVJanssen Research & Development LLC

最高研发阶段批准上市

首次获批日期

日本 (1982-06-15),

慢性胃炎婴儿腹泻胃下垂+ [4]

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C22H24ClN5O2

InChIKeyFGXWKSZFVQUSTL-UHFFFAOYSA-N

CAS号57808-66-9

关联

98

项与多潘立酮相关的临床试验

IRCT20190810044500N28 / Suspended临床2期IIT

Investigating the effectiveness and safety of three treatment methods with probiotics, domperidone and their combination compared to the control group in preventing VAP in severe brain trauma patients admitted to the special care units of Shahid Rahmonun Hospital in Yazd

开始日期2024-10-22

申办/合作机构-

CTRI/2024/10/074691 / Not yet recruiting临床3期IIT

A randomised controlled clinical trial on Qilat e Laban oligogalactia due to hypoprolactinemia with Foeniculum vulgare in comparison with Domperidone - Nil

开始日期2024-10-15

申办/合作机构-

IRCT20220508054780N5 / SuspendedN/AIIT

A clinical trial to compare the effectiveness of domperidone with erythromycin on preventing gastric residual volume in patients admitted to the intensive care unit

开始日期2024-07-22

申办/合作机构

Mashhad University of Medical Sciences

100 项与多潘立酮相关的临床结果

登录后查看更多信息

100 项与多潘立酮相关的转化医学

登录后查看更多信息

100 项与多潘立酮相关的专利（医药）

登录后查看更多信息

2,490

项与多潘立酮相关的文献（医药）

2025-02-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

A simple eco-friendly spectrofluorimetric resolution approach for the simultaneous determination of Naproxen and Domperidone in pharmaceutical formulation and human plasma; assessment of method greenness

Article

作者: Mostafa, Noha S ; Abdel Rahman, Mona A. ; Ayish, Nada S ; Mostafa, Noha S. ; Abdel Rahman, Mona A ; Ayish, Nada S.

Designing new verified methods for the determination of pharmaceutical compounds in their specified formulation without prior separation and with high sensitivity taking in consideration analytical performance and simplicity has become a major concern of pharmaceutical quality control units. In the present work, a new simple and eco-friendly spectrofluorimetric method was developed and validated for the determination of Naproxen (NAP) and Domperidone (DOM) in their binary mixture, pharmaceutical formulation in addition to human plasma without prior separation. The proposed method is based on measuring the second derivative fluorescence intensity for NAP at 345 nm and for DOM at 292 after excitation at 235 nm without any interference from each other. All the variables affecting fluorescence intensity were studied and optimized. The proposed method showed excellent sensitivity with limit of detection (LOD) 12.286 ng/mL and 3.240 ng/mL for NAP and DOM respectively. In compliance with the ICH requirements, the optimized method was validated and was successfully utilized for the determination of both drugs in their pharmaceutical formulation and human plasma. Finally, the greenness of the proposed method was assessed using different assessment tools.

2024-11-01·JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Assessment of antiemetic activity of dihydrocoumarin: In vivo and in silico approaches on receptor binding affinity and modulatory effects

Article

作者: Luna, Afroza Akter ; Chowdhury, Raihan ; Eity, Tanzila Akter ; Saim, Md Abu ; Saim, Md. Abu ; Bhuia, Md. Shimul ; Hossain, Kazi Nadim ; Saim, Abu ; Islam, Muhammad Torequl ; Bhuia, Md Shimul ; Ahammed, Nowreen Tabassum ; Munshi, Md Hanif ; Munshi, Hanif ; Bhuia, Shimul ; Munshi, Md. Hanif ; Ansari, Siddique Akber

Dihydrocoumarin (DCN) is a natural compound widely used in the flavor industry and has antioxidant and anti-inflammatory properties. However, its potential antiemetic effects on gastrointestinal disturbances remain untested. This study emphasizes assessing the antiemetic properties of the natural aromatic compound DCN using copper sulfate (CuSO₄.5H₂O)-induced emetic model on chicks, and an in silico approach was also adopted to estimate the possible underlying mechanisms. Two doses (25 and 50 mg/kg b.w.) of DCN and several referral drugs considered positive controls (PCs), including domperidone (6 mg/kg), hyoscine (21 mg/kg), aprepitant (16 mg/kg), diphenhydramine (10 mg/kg), and ondansetron (5 mg/kg), were orally administered to chicks. The vehicle was provided as the control group. Co-treatments of DCN with referral drugs were also provided to chicks to evaluate the modulatory action of the test compound. According to the results, DCN delayed the emetic onset and decreased the frequency of retches in a dose-dependent manner compared to the vehicle group. DCN (50 mg/kg) represented a notable delayed latency period (61.17 ± 4.12 s) and a diminished number of retchings (17.67 ± 1.82 times) compared to the control group. Further, in the co-treatments, DCN increased the latency period and reduced the number of retches, except for domperidone. In the in silico investigation, DCN showed notable binding affinity toward the D₂ (-7 kcal/mol), H₁ (-7.5 kcal/mol), and M₅ (-7 kcal/mol) receptors in the same binding site as the referral ligand. Our research indicates that DCN has mild antiemetic properties by interacting with the D₂, H₁, and M₅ receptors. Therefore, several pre-clinical and clinical studies are necessary to assess the effectiveness and safety profile of this food ingredient.

2024-09-19·International Breastfeeding Journal

Induced lactation in a transgender woman: case report.

Article

作者: Shirato, Nahoko ; Ninomiya, Noriko ; Nakatsuka, Mikiya ; Tanaka, Sachiko ; Wakabayashi, Hitomi ; Murase, Masahiko ; Kaneko, Mei ; Mizuno, Katsumi ; Ogawa, Mariko ; Gatanaga, Hiroyuki ; Tanaka, Miori ; Date, Midori ; Kamiya, Taro ; Ikebukuro, Shin ; Sekiguchi, Yuki ; Shiojiri, Daisuke ; Sekizawa, Akihiko

BACKGROUND:

Breastfeeding offers significant health benefits, but its practice and success can vary. While research on induced lactation in cisgender women has been documented, there is limited research on lactation induction in transgender women.

CASE PRESENTATION:

A 50-year-old transgender woman undergoing hormone therapy and living with a pregnant partner sought to co-feed using induced lactation. After approval by the hospital ethics committee, a regimen of estradiol, progesterone, and domperidone was initiated, accompanied by nipple stimulation. Lactation was successfully induced and maintained, with milk composition analysis indicating high levels of protein and other key nutrients. This case, the seventh reported, highlights the complexity of lactation induction in transgender women, considering factors such as age, obesity, and insulin resistance. The nutrient profile of the milk suggests its suitability for infant feeding, despite some differences from typical human milk.

CONCLUSIONS:

Induced lactation is feasible in transgender women, expanding the understanding of non-puerperal lactation and its potential in diverse family structures. Further research is warranted to optimize lactation induction protocols in transgender women.

44

项与多潘立酮相关的新闻（医药）

2024-05-30

·Firstwordpharma

CinRx reloads with $73M to spawn more biotech startups, advance obesity drugs

Biotech accelerator CinRx Pharma has secured an additional $73 million in financing to support its existing spinouts, created via its hub-and-spoke business model, as well as to pursue new programmes in areas with high unmet medical need. The latest infusion of capital, which brings its total funding to $176 million, was raised from prior investors including industry insiders and high-net-worth individuals. The new funding will enable CinRx to “replicate our proven asset selection process to identify and accelerate more promising new programs with high potential to impact patients’ quality of life,” according to Jon Isaacsohn, chief executive of CinRx Pharma.Seven CinCosTo date, CinRx has created seven portfolio companies – so-called "CinCos" – of which five are focused on cardiovascular, metabolic or gastrointestinal disorders. Most notably, hypertension drug developer CinCor was acquired by AstraZeneca last year for $1.3 billion upfront. The other four spinouts – CinFina, CinDome, CinPhloro and vTv Therapeutics – are focused on treatments for obesity, gastroparesis, irritable bowel syndrome and hypoglycaemia, respectively. CinFina’s four-candidate pipeline was in-licensed from Johnson & Johnson’s Jassen Pharmaceuticals unit and comprises two obesity assets in Phase I testing, along with a pair of preclinical programmes. CinDome’s lead candidate is deudomperidone (CIN-102), a dopamine D2/D3 agonist in a Phase II study of adults with diabetic gastroparesis; data are due next year.CinPhloro was built to develop CIN-103, a small molecule, pulsatile-release formulation of phloroglucinol modified to require less frequent dosing. The candidate is in a Phase II trial in patients with irritable bowel syndrome with diarrhoea, which is expected to wrap in 2025.The most advanced programme belongs to vTv Therapeutics, whose TTP399 – an oral, small molecule, liver selective glucokinase activator – is in a Phase III study as an adjunct therapy to insulin to manage hypoglycaemia in patients with type 1 diabetes.

临床2期并购临床1期临床3期

2024-05-30

·BioSpace

CinRx Pharma Announces Additional $73 Million Financing

Financing brings total funds raised to $176M to advance diverse portfolio of high-impact medicines and expand efforts to additional high unmet needs Current portfolio of CinCos include two clinical-stage obesity therapeutics, two Phase 2 gastrointestinal programs and several pre-clinical programs CINCINNATI--(BUSINESS WIRE)-- CinRx Pharma, a hub-and-spoke biotech accelerating high-impact medicines, today announced the closing of a $73 million financing, bringing the total funds raised to $176 million. Participants in the round include prior investors comprised of industry insiders and high-net-worth individuals. To date, CinRx has launched five companies (“CinCos”) focused primarily on cardiovascular, metabolic and gastrointestinal conditions. In addition to its company creation function, CinRx has forged several CINergy partnerships with existing companies. CinRx plans to use the funds to advance development of its existing portfolio programs and assets to expand in key areas of high unmet medical need. “Our early financings totaling $103 million supported the construction and progression of our seven-company portfolio. Notably, this included the formation, advancement and exit of CinCor Pharma ahead of its $1.8 billion acquisition, underscoring the success of our incredibly effective team and validation of our efficient business model,” said Dr. Jon Isaacsohn, Founder and Chief Executive Officer at CinRx Pharma. “With this infusion of capital, we will continue rapid advancement of existing programs and replicate our proven asset selection process to identify and accelerate more promising new programs with high potential to impact patients’ quality of life.” CinRx’s portfolio of CinCos are managed by a lean team of scientific, technical and drug development experts with decades of experience treating patients and supporting thousands of clinical development programs. Each CinCo was created through a rigorous asset selection process to identify novel therapies with the potential to address significant unmet medical needs and meaningfully reduce disease burden for patients. CinCor Pharma was created to advance baxdrostat (CIN-107), a highly selective, oral small molecule inhibitor of aldosterone synthase for the treatment of hypertension and other cardiorenal conditions from a license agreement with Roche in 2019. CinRx led the clinical design and execution of baxdrostat, and was responsible for CinCor’s successful Series A and Series B financings to fund its early development through its $194 million IPO in 2022. In early 2023, CinCor was acquired by AstraZeneca in a deal worth $1.3 billion upfront and an additional $500 million in biobucks. CinFina Pharma is developing a pipeline of four therapies, in-licensed from Janssen Pharmaceuticals, aimed at providing safe, tolerable and durable options for treating obesity. In March 2024, CinFina announced the dosing of the first patients in a Phase 1 trial of CIN-110, a PYY analog. Upcoming milestones include initiation of a Phase 2 study evaluating CIN-109, a novel GDF-15 molecule focusing on body composition and lean body mass preservation, with and without semaglutide. Additional preclinical development is ongoing to support Investigational New Drug (IND) application submissions for CIN-209 and CIN-210, which are both dual-agonists utilizing GLP-1 therapy in combination with the aforementioned mechanisms of action. CinDome Pharma is developing deudomperidone (CIN-102) as a potential safe, chronic treatment for gastroparesis. Deudomperidone is a novel formulation of a well-known dopamine D2/D3 agonist, domperidone. In May 2023, CinDome presented encouraging QT study data at the 2023 Digestive Disease Week (DDW) Conference. CinDome recently raised $40 million in a Series B financing from Perceptive Advisors and CinRx, and is actively enrolling the Phase 2 envision3D study for adults with diabetic gastroparesis, expected to read out in 2025. CinPhloro Pharma is progressing CIN-103, a small molecule for the long-term management of irritable bowel syndrome with diarrhea (IBS-D). CIN-103 is a pulsatile-release formulation of phloroglucinol, an approved therapy in select countries outside of the U.S., modified for sustained exposure and less frequent dosing. In February 2024, CinPhloro dosed the first patients in the Phase 2 enviva study to evaluate the safety, efficacy and tolerability of CIN-103 for IBS-D. CinPhloro is actively enrolling the enviva study, which is expected to complete in 2025. About CinRx Pharma: CinRx Pharma is a biotech company advancing a diverse portfolio of high-impact medicines through clinical development with a unique hub-and-spoke business model. CinRx’s approach combines financing with the efficient progression of therapeutic candidates within its portfolio, each managed by CinRx’s central infrastructure and operating team. Current CinCos address areas of high unmet medical need including metabolic, gastrointestinal and oncology. Differentiated by an asset selection process agnostic to therapeutic area, a strategic CRO partnership, and insights from thousands of development programs, CinRx identifies, funds and accelerates promising drugs with the potential to have the highest impact on patients’ quality of life. CinRx Pharma is headquartered in Cincinnati, Ohio. For more information, please visit or follow the company on X and LinkedIn.

临床1期临床2期引进/卖出并购

2024-05-20

·创鉴汇

8家创新药公司获融资！诺奖得主创立蛋白降解疗法公司获过亿美元融资 | 一周融资

▎药明康德内容团队编辑据创鉴汇不完全统计，上周（5月13日至5月19日）全球大健康领域共披露融资事件29起，总额超67亿元。按照金额划分，亿元及以上融资15起。按照已披露的融资轮次划分，早期融资（B轮以前）11起，中后期融资（B轮及以后）13起。生物医药领域共8家公司获融资，涉及药物类型包含单克隆抗体、蛋白降解疗法、细胞基因疗法等。#01Uniquity Bio完成3亿美元融资关键词：单克隆抗体研发公司最新融资：3亿美元未知轮本轮投资机构：Blackstone Life Sciences5月15日，黑石（Blackstone）集团正式推出Uniquity Bio公司，这是一家专注于免疫学和炎症的临床阶段药物开发公司。该公司针对胸腺基质淋巴细胞生成素（TSLP）的单克隆抗体solrikitug的2期临床试验的IND申请已获得美国FDA许可，并从黑石集团获得高达3亿美元的资金支持，用于推进该药物在多个适应症中的研发。Solrikitug是一种高效的抗TSLP单克隆抗体，能阻止TSLP与其受体的结合。鉴于TSLP在炎症级联反应顶端的主控调节因子地位，solrikitug在广泛的免疫学和炎症疾病中具有潜在的应用价值。Solrikitug最初由默沙东（MSD）公司开发，Uniquity Bio获得了这款抗体疗法的开发权益。#02Lycia Therapeutics完成1.07亿美元C轮融资关键词：新型蛋白降解疗法研发公司最新融资：1.07亿美元C轮本轮投资机构：Alexandria Venture Investments、Blue Owl Healthcare Opportunities、Eli Lilly and Company、Franklin Templeton等5月13日，Lycia Therapeutics宣布完成超额认购的1.07亿美元C轮融资。Lycia Therapeutics是一家细胞外蛋白降解疗法开发公司，以专有的溶酶体靶向嵌合体（LYTACs）平台为核心技术，旨在靶向未开发的细胞外蛋白质组，以开发针对自身免疫性和炎症类难治疾病疾病药物。据悉，本轮融资将用于推进其自身免疫性疾病和炎症性疾病的临床先导项目。Lycia公司由2022年诺贝尔化学奖得主，斯坦福大学的Carolyn Bertozzi教授联合创建。在2021年，Lycia与礼来公司达成高达16亿美元的研发合作，利用LYTAC技术发现、开发和推广靶向创新靶点的蛋白降解疗法，涉及免疫学和疼痛等多个治疗领域。#03Ajax Therapeutics完成9500万美元C轮融资关键词：小分子药物研发公司最新融资：9500万美元C轮本轮投资机构：Boxer Capital、EcoR1 Capital、Eli Lilly and Company、Goldman Sachs Alternatives等5月13日，Ajax Therapeutics宣布完成9500万美元C轮超额认购。融资所得将用于支持Ajax潜在的“First-in-class”II型JAK2抑制剂AJ1-11095的临床开发，用于治疗骨髓纤维化，并推进该公司的骨髓增生性肿瘤（MPN）治疗管线。Ajax Therapeutics是一家应用计算化学和基于结构的技术开发新型血液恶性肿瘤小分子的生物技术公司。AJ1-11095由Ajax设计，使用基于结构的药物设计和大规模计算方法，选择性地结合JAK2激酶的II型构象，与目前批准的所有JAK2抑制剂相比，在疾病修饰方面提供潜在更好的疗效。#04CinDome Pharma完成4000万美元B轮融资关键词：胃肠道疾病药物研发公司最新融资：4000万美元B轮本轮投资机构：CinRx Pharma、Perceptive Advisors5月16日，CinDome Pharma致力于推进胃轻瘫的慢性疗法，该公司今天宣布获得4000万美元的B轮融资。这项资本将支持deudomperidone在二期envision3D研究中招募胃轻瘫患者，为公司进行注册试验做好准备。根据公司提供信息，美国有近1600万成年患者出现胃轻瘫症状，一种可以长期使用的安全且有效的治疗方法仍然是一个重大的未满足需求。CinDome研发的deudomperidone是工程化制剂的D2/D3对抗剂多珀酮，这是全球胃轻瘫的首选治疗方法，但在美国尚未获批。#05济因生物完成数千万人民币天使+轮融资关键词：肿瘤基因与细胞疗法研发公司最新融资：数千万元天使+轮本轮投资机构：天创资本5月15日，济因生物完成了数千万人民币天使+轮融资，由天创资本独家投资。济因生物聚焦通用型细胞与基因治疗产品的开发，拥有iPSC重编程及定向分化、体内靶向递送等技术平台。该公司以体内CAR-T、iPS（诱导多能干细胞）来源CAR-iNK为特色管线，致力于提供患者可及的细胞与基因治疗产品。该公司计划将此轮融资主要用于核心技术平台的优化升级以及体内CAR-T管线的临床阶段工作推进。#06Turbine获投资，推动AI细胞模拟药物研发应用关键词：人工智能药物发现公司最新融资：战略投资本轮投资机构：Accenture Ventures5月16日，Accenture对Turbine完成了战略投资。Turbine是一家AI细胞模拟公司，正在构建一个解释人体生物学的平台以加速药物开发。Turbine的核心技术Simulated Cell平台利用机器学习来了解人类细胞如何做出“决策”。该平台对细胞内和细胞周围的分子相互作用进行了复杂的建模，实现了在物理世界中几乎不可能实现的虚拟实验，并揭示了驱动疾病和对治疗产生响应的机制。据悉，Accenture的投资将帮助Turbine进一步将其能力扩展到全球生物医药公司，指导和加速关键的药物开发工作流程。读者们请星标⭐创鉴汇，第一时间收到推送免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转发/复制至其他平台。转发授权请在「创鉴汇」微信公众号留言联系我们。更多数据内容推荐点击“在看”，分享创鉴汇健康新动态

临床申请基因疗法细胞疗法

100 项与多潘立酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01745	多潘立酮	A03FA03	DB01184

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
胃肠道疾病	日本	Kyowa Hakko Kirin Pharma, Inc.	1982-09-01
恶心	日本	Kyowa Hakko Kirin Pharma, Inc.	1982-09-01
呕吐	日本	Kyowa Hakko Kirin Pharma, Inc.	1982-09-01
慢性胃炎	日本	Kyowa Kirin Co., Ltd.	1982-06-15
婴儿腹泻	日本	Kyowa Kirin Co., Ltd.	1982-06-15
胃下垂	日本	Kyowa Kirin Co., Ltd.	1982-06-15
胃灼热	日本	Kyowa Kirin Co., Ltd.	1982-06-15
恶心和呕吐	日本	Kyowa Kirin Co., Ltd.	1982-06-15
胃切除术后综合征	日本	Kyowa Kirin Co., Ltd.	1982-06-15
呼吸道感染	日本	Kyowa Kirin Co., Ltd.	1982-06-15

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胃肠炎	临床3期	奥地利	Janssen-Cilag International NV	2015-12-07
胃肠炎	临床3期	比利时	Janssen-Cilag International NV	2015-12-07
胃肠炎	临床3期	俄罗斯	Janssen-Cilag International NV	2015-12-07
胃肠炎	临床3期	南非	Janssen-Cilag International NV	2015-12-07
胃肠炎	临床3期	西班牙	Janssen-Cilag International NV	2015-12-07
胃肠炎	临床3期	英国	Janssen-Cilag International NV	2015-12-07
诺如病毒感染	临床3期	奥地利	Janssen-Cilag International NV	2015-12-07
诺如病毒感染	临床3期	比利时	Janssen-Cilag International NV	2015-12-07
诺如病毒感染	临床3期	俄罗斯	Janssen-Cilag International NV	2015-12-07
诺如病毒感染	临床3期	南非	Janssen-Cilag International NV	2015-12-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04024865 (Pubmed)	N/A	-	184,929	Domperidone	築艱餘憲衊鬱觸廠醖鹽(鹽蓋繭顧製淵構獵淵構) = 壓網遞窪選簾淵襯願膚鬱襯淵築願廠簾廠蓋築 (製鬱餘願鏇鬱淵衊築製 )	-	2021-04-01
TCTR2020091008 (Pubmed \| Breastfeed Med)	N/A	-	-	Domperidone	襯窪衊鹽齋憲願蓋繭築(積壓窪廠鬱蓋齋襯膚襯) = 鹹鹹鏇製積齋齋構顧網築壓鑰鹹餘網願顧築築 (願餘獵糧鬱遞顧積簾選 ) 更多	-	2021-03-01
TCTR2020091008 (Pubmed \| Breastfeed Med)	N/A	-	-	Placebo	襯窪衊鹽齋憲願蓋繭築(積壓窪廠鬱蓋齋襯膚襯) = 夢襯顧鑰鑰願餘憲鑰糧築壓鑰鹹餘網願顧築築 (願餘獵糧鬱遞顧積簾選 ) 更多	-	2021-03-01
NCT03662113 (Pubmed \| Transl Pediatr)	N/A	-	200	Domperidone	齋選壓夢齋鬱顧選艱築(襯鹹鹹選築夢鏇鏇鹽簾) = 鬱選願齋鹹齋艱網選衊壓膚壓壓獵簾憲築觸網 (齋膚積築醖積繭醖憲積, 44.8 ~ 117.5) 更多	不佳	2021-02-01
NCT03662113 (Pubmed \| Transl Pediatr)	N/A	-	200	domperidone (Control)	齋選壓夢齋鬱顧選艱築(襯鹹鹹選築夢鏇鏇鹽簾) = 淵壓淵築淵憲糧顧淵願壓膚壓壓獵簾憲築觸網 (齋膚積築醖積繭醖憲積, 42.0 ~ 128.0) 更多	不佳	2021-02-01
NCT02308137 (not available, ACTRIMS2020)	临床2期	继发进展型多发性硬化 prolactin levels	110	Domperidone 10mg	鹹繭膚繭蓋廠觸襯構簾(蓋醖餘淵觸鬱廠顧襯蓋) = 窪壓顧簾廠艱範壓積遞築獵餘夢鏇鏇蓋窪顧選 (鑰夢獵餘窪範鏇餘鹽膚 )	不佳	2020-05-11
NCT02493049 (ECTRIMS2018)	临床2期	复发-缓解型多发性硬化追加	15	Domperidone	壓願積壓網衊鏇範餘醖(蓋選糧積夢繭簾獵餘糧) = 鏇鹹鹽選獵築鬱鑰繭製製鹽顧齋鏇繭窪餘鏇壓 (廠膚憲繭觸範觸餘簾製, 5.2)	-	2018-10-09
NCT00760461 (CTgov)	临床2期	胃轻瘫	44	Domperidone	築醖齋鹹夢鬱餘鹽醖鏇(鏇艱鹽獵醖醖餘廠齋鏇) = 窪選遞鑰廠繭鏇鏇範積齋壓鑰淵蓋淵壓餘積夢 (範選艱鬱獵鑰繭衊蓋襯, 壓醖齋選窪繭積鬱遞衊 ~ 憲衊鑰襯網鑰願齋鏇鏇) 更多	-	2017-08-18
NCT01878526 (GERD-SSc, CTgov)	临床3期	系统性硬皮病 \| 胃食管反流	80	placebo (for domperidone)+Alginic acid (Omeprazole Plus Alginic Acid and Placebo of Domperidone)	構醖獵憲觸衊鬱選製顧(獵餘蓋糧選繭積範遞鹹) = 鬱窪網窪夢鏇醖範鏇鹽觸願網壓艱選鹹觸願繭 (鑰窪窪遞艱鑰淵夢願壓, 獵糧齋鏇鏇蓋憲淵廠廠 ~ 淵鏇夢築鏇鏇繭餘顧觸) 更多	-	2017-03-27
NCT01878526 (GERD-SSc, CTgov)	临床3期	系统性硬皮病 \| 胃食管反流	80	placebo (of alginic acid)+Domperidone (Omeprazole Plus Domperidone and Placebo of Alginic Acid)	構醖獵憲觸衊鬱選製顧(獵餘蓋糧選繭積範遞鹹) = 糧觸構夢夢繭衊糧膚鬱觸願網壓艱選鹹觸願繭 (鑰窪窪遞艱鑰淵夢願壓, 窪顧餘繭蓋淵淵鬱鬱簾 ~ 積衊鬱蓋選構憲醖選鹹) 更多	-	2017-03-27
NCT01878526 (Pubmed \| Rheumatology (Oxford))	临床3期	系统性硬皮病 \| 胃食管反流追加	80	Domperidone plus algycon placebo	鑰蓋製衊衊艱獵構網艱(鏇膚糧築觸艱餘衊膚憲) = 遞獵夢繭壓蓋獵積網壓廠憲齋蓋願簾淵壓觸齋 (觸製壓窪網鏇構製鹹壓 )	-	2017-02-01
NCT01878526 (Pubmed \| Rheumatology (Oxford))	临床3期	系统性硬皮病 \| 胃食管反流追加	80	Algycon plus domperidone placebo	鑰蓋製衊衊艱獵構網艱(鏇膚糧築觸艱餘衊膚憲) = 憲憲觸鬱顧蓋鹹築膚顧廠憲齋蓋願簾淵壓觸齋 (觸製壓窪網鏇構製鹹壓 )	-	2017-02-01
NCT01711918 (CTgov)	N/A	恶心 \| 胃轻瘫 \| 呕吐	9	Domperidone	鬱餘壓鹹艱製積夢醖鹽(獵醖選衊淵製鏇壓繭願) = 繭顧憲膚鹹糧遞窪簾繭鹽醖醖簾構構選鹹願觸 (鏇醖廠鬱窪簾艱製願顧, 築衊憲艱淵鹹選襯襯鹽 ~ 糧積鏇醖築齋網製顧網) 更多	-	2016-12-19
P2.345 (AAN2016)	N/A	-	101	Domperidone	鬱鏇繭衊鹹餘願遞衊選(選膚艱壓鹽構觸衊淵餘) = only one potential cardiac event (dizziness) was observed 醖憲鏇願製廠憲壓齋選 (網餘簾範鬱築蓋範網齋 )	积极	2016-04-05